Publications by authors named "Michael Sebag"

Claim this Profile
I
Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy.
C Arianne Buchan, Gerard Agbayani, Katrina Hueniken, Abi Vijenthira, Michael Sebag

Transplant Cell Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database.
Julia Varghese, Christopher P Venner, Martha Louzada, Donna Reece, Darrell White, Michael Sebag

Clin Lymphoma Myeloma Leuk· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies.
Abi Vijenthira, Sita Bhella, Katrina Hueniken, Allison M Wilkin, Michael Sebag

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database.
Rayan Kaedbey, Christopher P Venner, Donna Reece, Kevin Hay, Engin Gul, Michael Sebag

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis.
Arleigh McCurdy, Engin Gul, Donna Reece, Michael P Chu, Victor H Jimenez-Zepeda, Michael Sebag

Clin Lymphoma Myeloma Leuk· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada.
Hira S Mian, Alissa Visram, Steven Chun-Min Shih, Suzanne Trudel, Annette E Hay, Michael Sebag

Clin Lymphoma Myeloma Leuk· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma.
Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard, Richard LeBlanc, Julie Côté, Michael Sebag

Curr Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
Yael C Cohen, Hila Magen, Moshe Gatt, Michael Sebag, Kihyun Kim

N Engl J Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014.
Nizar J Bahlis, Christy Samaras, Donna Reece, Michael Sebag, Jeffrey Matous

Clin Lymphoma Myeloma Leuk· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.
Mégane Tanguay, Jean Roy, Jiandong Su, Engin Gul, Donna Reece, Michael Sebag

Cancer Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
Sita Bhella, Allison M Wilkin, Katrina Hueniken, Abi Vijenthira, Michael Sebag

Vaccine· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database.
Christopher P Venner, Peter Duggan, Kevin Song, Donna Reece, Smriti Sharma, Michael Sebag

Transplant Cell Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database.
Rayan Kaedbey, Donna Reece, Christopher P Venner, Arleigh McCurdy, Jiandong Su, Michael Sebag

EJHaem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs.
Connor Prosty, Khaled Katergi, Alex Nguyen, Owen Dan Luo, Mark Sorin, Michael Sebag

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, and Colorectal Cancer.
Rebecca Boutin, Hiu-Fung Lee, Tian Lai Guan, Tan Trieu Nguyen, Xian Fang Huang, Michael Sebag

J Med Chem· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
Richard LeBlanc, Hira Mian, Donna Reece, Jiandong Su, Esther Masih-Khan, Michael Sebag

Eur J Haematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Michael Sebag

Nat Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
Julie Côté, Richard LeBlanc, Hira Mian, Michael P Chu, Arleigh McCurdy, Michael Sebag

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
Arleigh McCurdy, Hira Mian, Richard LeBlanc, Victor H Jimenez-Zepeda, Jiandong Su, Michael Sebag

Blood Cancer J· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma.
Steven Findlay, Remya Nair, Ronald A Merrill, Zafir Kaiser, Alexandre Cajelot, Michael Sebag

Blood Adv· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.
Julie Stakiw, Shruthi Kodad, Richard LeBlanc, Michael Sebag, Annette E Hay

Clin Lymphoma Myeloma Leuk· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
Arleigh McCurdy, Hira Mian, Richard LeBlanc, Victor H Jimenez-Zepeda, Jiandong Su, Michael Sebag

Blood Cancer J· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved platform for breast cancer circulating tumor cell enrichment and characterization with next-generation sequencing technology.
Catalin Mihalcioiu, Jiarong Li, Dunarel Badescu, Anne Camirand, Nathaniel Kremer, Michael Sebag

Am J Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
Muhamed Baljevic, Cristina Gasparetto, Gary J Schiller, Sascha A Tuchman, Natalie S Callander, Michael Sebag

EJHaem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
Arleigh McCurdy, Martha Louzada, Christopher P Venner, Alissa Visram, Esther Masih-Khan, Michael Sebag

EJHaem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis